Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib plus Fulvestrant in Advanced Breast Cancer
NCT00754325Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2008
- Primary completion
- Nov 2011
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dasatinib in breast cancer (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-Free Survival up to 5 years. Started Sep 2008; status: completed.
02
Drugs
dasatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00754325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00754325.